羟考酮
外观
(重定向自奧施康定)
![]() | |
![]() | |
临床资料 | |
---|---|
读音 | ɒksɪˈkəʊdəʊn |
商品名 | OxyContin, Endone, others |
其他名称 | Eukodal, eucodal; dihydrohydroxycodeinone, 7,8-dihydro-14-hydroxycodeinone, 6-deoxy-7,8-dihydro-14-hydroxy-3-O-methyl-6-oxomorphine[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682132 |
核准状况 | |
怀孕分级 | |
依赖性 | 高[3] |
给药途径 | 口服给药, 口腔黏膜吸收, 肌肉注射, 静脉注射, 鼻腔给药, 皮下注射, 经皮给药, 直肠给药, 硬脊膜外麻醉[4] |
ATC码 | |
法律规范状态 | |
法律规范 |
|
药物动力学数据 | |
生物利用度 | 口服: 60–87%[5][6] |
血浆蛋白结合率 | 45%[5] |
排泄途径 | 尿 (83%)[5] |
识别信息 | |
| |
CAS号 | 76-42-6 ![]() |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.874 |
化学信息 | |
化学式 | C18H21NO4 |
摩尔质量 | 315.37 g·mol−1 |
3D模型(JSmol) | |
熔点 | 219 °C(426 °F) |
水溶性 | 166 (HCl) |
| |
|
羟考酮(英语:Oxycodone,或译奥施康定)是一种用于缓解疼痛的口服鸦片类药物,于1916年首次在德国制成。[7]它具有高度成瘾性[8],因此容易被滥用。 [9][10][9]服用药物后该药在十五分钟内就能开始缓解疼痛,药效可以持续六个小时。[9]
该药常见的副作用有欣快、便秘、恶心、呕吐、食欲不振、嗜睡、头晕、瘙痒、口干和出汗。[9]严重的副作用可能包括上瘾、物质依赖、物质滥用、易怒、抑郁、狂躁、谵妄、幻觉、换气不足、心跳过缓和低血压。[9]
参考文献
[编辑]- ^ O'Neil MJ (编). The Merck index 14th. Whitehouse Station, NJ: Merck & Co. 2006. ISBN 978-0-911910-00-1.
- ^ Oxycodone Use During Pregnancy. Drugs.com. 14 October 2019 [12 April 2020]. (原始内容存档于2020-06-19).
- ^ Bonewit-West K, Hunt SA, Applegate E. Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. 2012: 571 [2022-07-10]. ISBN 978-1-4557-0150-6. (原始内容存档于2020-07-28) (英语).
- ^ Kalso E. Oxycodone. Journal of Pain and Symptom Management. May 2005, 29 (5 Suppl): S47–S56. PMID 15907646. doi:10.1016/j.jpainsymman.2005.01.010
.
- ^ 5.0 5.1 5.2 Roxicodone, OxyContin (oxycodone) dosing, indications, interactions, adverse effects, and more. Medscape Reference. WebMD. [8 April 2014]. (原始内容存档于2014-04-13).
- ^ Elliott JA, Smith HS. Handbook of Acute Pain Management. CRC Press. 19 April 2016: 82– [2022-07-10]. ISBN 978-1-4665-9635-1. (原始内容存档于2021-04-17).
- ^ Drug discovery: a history. Hoboken, NJ: Wiley. 2005: 119. ISBN 978-0-471-89980-8.
- ^ Remillard D, Kaye AD, McAnally H. Oxycodone's Unparalleled Addictive Potential: Is it Time for a Moratorium?. Current Pain and Headache Reports. February 2019, 23 (2): 15. PMID 30820686. S2CID 73488265. doi:10.1007/s11916-019-0751-7.
- ^ 9.0 9.1 9.2 9.3 9.4 Oxycodone Monograph for Professionals. Drugs.com. AHFS. [28 December 2018]. (原始内容存档于2018-12-28).
- ^ Pergolizzi JV, Taylor R, LeQuang JA, Raffa RB. Managing severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product. Journal of Pain Research. 2018, 11: 301–311. PMC 5810535
. PMID 29445297. doi:10.2147/JPR.S127602.